Interstitial lung disease due to anti-TNF use in the treatment of psoriasis()()

Psoriasis is a chronic inflammatory disease that affects the skin variably, according to genetic and environmental factors. Some patients may benefit from systemic treatment with immunobiological agents, drugs that can be accompanied by several adverse effects. A case of a 58-year-old patient underg...

Descripción completa

Detalles Bibliográficos
Autores principales: Turíbio, Débora Dorneles Cunha de Queiroz, Oliveira, Francisco Clitson Sousa, Barreto, Sandra Maria Fonseca, Jabour, Thaís Barros Felippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Sociedade Brasileira de Dermatologia 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8245706/
https://www.ncbi.nlm.nih.gov/pubmed/34001401
http://dx.doi.org/10.1016/j.abd.2020.08.016
Descripción
Sumario:Psoriasis is a chronic inflammatory disease that affects the skin variably, according to genetic and environmental factors. Some patients may benefit from systemic treatment with immunobiological agents, drugs that can be accompanied by several adverse effects. A case of a 58-year-old patient undergoing treatment for psoriasis with adalimumab for five years is reported. Alterations compatible with interstitial pneumonia were detected with important regression after adalimumab discontinuation. This case is relevant due to the scarcity of reports on late pulmonary adverse effect of anti-TNF treatment of psoriasis.

Ejemplares similares